Articles From: Acquisition of Strike Technologies Services' Microwave Network Business Completed to Actavis To Buy Allergan In $66 Billion Deal--Update


2014/10/31
Acquisition of Strike Technologies Services' Microwave Network Business Completed Canada NewsWire LONDON , Oct.
Sign-up for Acquisition of Strike Technologies Services' Microwave Network Business Completed investment picks
SAN DIEGO and WORCESTER, Mass., Nov.
Sign-up for Acquisition of World Energy Solutions, Inc. (XWES) by EnerNOC, Inc. (ENOC) May Not Be in Shareholders' Best Interests investment picks
2014/11/12
BENTONVILLE, Ark., Nov.
Sign-up for Acres for America Announces Grant Recipients for 2014 investment picks
Advanced Workflow Solution Will Support Next Decade of Geospatial Data Growth for Service Provider SAN JOSE, Calif.
Sign-up for ACRI-ST Deploys Quantum's StorNext 5 System To Manage And Preserve Critical Satellite Imaging And Remote Sensor Data investment picks
2014/10/6
By Tess Stynes Actavis PLC reached an agreement to acquire specialty pharmaceutical company Durata Therapeutics Inc. in a deal the companies valued at about $675 million, which is expected to strengthen Actavis's business that focuses on infectious diseases.
Sign-up for Actavis agrees to acquire Durata Therapeutics investment picks
DUBLIN and CHICAGO , Oct.
Sign-up for Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata investment picks
DUBLIN , Nov.
Sign-up for Actavis Announces Planned Retirement of R. Todd Joyce in Early 2015 investment picks
DUBLIN , Oct.
Sign-up for Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent investment picks
DUBLIN , Sept.
Sign-up for Actavis Confirms Generic Butrans® Patent Challenge investment picks
DUBLIN , Oct.
Sign-up for Actavis Confirms Generic Quillivant XR® Patent Challenge investment picks
DUBLIN , Dec.
Sign-up for Actavis Launches Generic Version of Celebrex® investment picks
DUBLIN , Dec.
Sign-up for Actavis Launches Generic Version of Intuniv® investment picks
- Expertise in global finance, M&A, business development - - Will join Actavis effective December 8, 2014 - DUBLIN , Nov.
Sign-up for Actavis Names Maria Teresa Hilado Chief Financial Officer investment picks
- Increases Second Half Non-GAAP EPS Forecast to $6.60-$6.70 - - 158% Increase in Third Quarter 2014 Adjusted EBITDA to $1.3 billion - - North American Brands Revenues of $1.6 billion; North American Generics and International Revenues of $1.6 billion - - Debt Repayment of ~$750 million During Quarter - - Business Development Initiatives Expand Portfolios; Significant Progress in Integration/Synergy Capture - - GAAP Loss Per Diluted Share in Third Quarter of $3.95 - DUBLIN , Nov.
Sign-up for Actavis Net Revenue Increases 83% to $3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to $3.19 investment picks
2014/11/18
By Chelsey Dulaney Actavis PLC outlined new details of its planned acquisition of Allergan Inc. on Tuesday, including plans to appoint two Allergan directors to its board and a $2.1 billion breakup fee.
Sign-up for Actavis Outlines Allergan Breakup Fee, Board Appointments investment picks
Actavis PLC (ACT) reportedly is in talks to purchase Salix Pharmaceuticals Ltd.
Sign-up for Actavis reportedly in talks to buy Salix Pharma investment picks
By Russ Britt, MarketWatch Actavis shares jump 5.5% while Allergan rises 1.4% LOS ANGELES (MarketWatch) -- This has got to be a new one in the merger game: the buyer's shares have gone up more than the company it's buying.
Sign-up for Actavis shares outpace buyout target's gains investment picks
Shares of Actavis Plc (ACT) rose more than 2% in afternoon trade Tuesday, after Bloomberg News reported that the company was approached by Pfizer Inc. (PFE) to discuss a possible deal.
Sign-up for Actavis shares rise on report of Pfizer approach investment picks
- Relamorelin is a Novel Peptide Ghrelin Agonist for Diabetic Gastroparesis - - Actavis Option to Purchase Rhythm Health, Inc. upon Successful Completion of Phase 2b Study - DUBLIN and BOSTON , Oct.
Sign-up for Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin investment picks
- Transaction Valued at $66 Billion or $219 per Share in Cash and Actavis Shares - - Fastest Growing, Most Dynamic Pharmaceutical Company in Global Healthcare - - Leading Blockbuster Franchises in Ophthalmology, Neurosciences/CNS, Medical Aesthetics/Dermatology/Plastic Surgery, Women's Health, Gastroenterology and Urology - - Positioned for Long-Term Double-Digit Organic Revenue and Earnings Growth - - Double-Digit Accretion to Non-GAAP EPS within First 12 Months - - Expands International Presence with Greater Market and Product Reach - - Projected Synergies of at Least $1.8 Billion while Maintaining R&D Commitment of Approximately $1.7 Billion - - Free Cash Flow Generation of more than $8 Billion expected in 2016 - - Investment Grade Rating Expected to be Maintained; Rapid Deleveraging to Below 3.5x Debt to Adjusted EBITDA within 12 Months - - Closing Anticipated in Q2 2015 - DUBLIN and IRVINE, Calif.
Sign-up for Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue investment picks
- Lead Product DALVANCE™ a Novel Antibiotic for Unmet Medical Need in Hospital and Outpatient Settings - - Enhances Actavis' Long-term Growth Profile 2015+ - - Experienced Development and Commercial Team Bolsters Actavis' Infectious Disease Expertise - - Leverages Actavis' Hospital Sales and Marketing Capabilities - DUBLIN, Ireland and CHICAGO , Oct.
Sign-up for Actavis to Acquire Durata Therapeutics, Inc. investment picks
By Jonathan D.
Sign-up for Actavis to buy Allergan in $66 billion deal investment picks
2014/11/17
By Jonathan D.
Sign-up for Actavis To Buy Allergan in $66 Billion Deal -- 5th Update investment picks
2014/11/17
By Jonathan D.
Sign-up for Actavis To Buy Allergan In $66 Billion Deal--2nd Update investment picks
2014/11/17
By Jonathan D.
Sign-up for Actavis To Buy Allergan In $66 Billion Deal--3rd Update investment picks
2014/11/17
By Jonathan D.
Sign-up for Actavis To Buy Allergan In $66 Billion Deal--4th Update investment picks
2014/11/17
By Jonathan D.
Sign-up for Actavis To Buy Allergan In $66 Billion Deal--Update investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Acquisition of Strike Technologies Services' Microwave Network Business Completed to Actavis To Buy Allergan In $66 Billion Deal--Update
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent